An analysis by curems.net, which compiles comparative studies (including Kalincik’s), shows that no DMT is superior to AHSCT, either in clinical or radiological outcomes.
Kalincik et al. ( #ECTRIMS 2025) compared #AHSCT (152 pts) vs anti-CD20 (Ocrelizumab 752, Rituximab 107).
#AHSCT showed better ARR and EDSS improvement, with no difference in worsening. No DMT outperforms AHSCT in #RRMS.
🟢 Highlights curems.net/benefits-of-...
Poster core.melbourne/wp-content/u...